Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
| Revenue (TTM) | $11.03B |
| Gross Profit (TTM) | $7.36B |
| EBITDA | $4.16B |
| Operating Margin | 33.60% |
| Return on Equity | 17.40% |
| Return on Assets | 10.50% |
| Revenue/Share (TTM) | $31.07 |
| Book Value | $49.31 |
| Price-to-Book | 8.15 |
| Price-to-Sales (TTM) | 11.09 |
| EV/Revenue | 13.04 |
| EV/EBITDA | 34.93 |
| Quarterly Earnings Growth (YoY) | 26.50% |
| Quarterly Revenue Growth (YoY) | 18.50% |
| Shares Outstanding | $354.16M |
| Float | $352.04M |
| % Insiders | 0.51% |
| % Institutions | 90.44% |
Volatility is currently expanding
Intuitive Surgical (ISRG) shares plummeted Friday after the maker of robotic surgical tools failed to raise the outlook for its flagship product despite better-than-expected second-quarter results.
ISRG beats second-quarter earnings and revenue estimates, but shares fall after hours as procedure growth slows sequentially despite strong placements.
GenAI creates new opportunities for ISRG, ALC and LIVN, even as regulatory, inflation and industry headwinds continue to pressure MedTech.
Intuitive Surgical (NASDAQ: ISRG) shares fell about 11% on Friday after the robotic surgery company reported second-quarter results that topped Wall Street expectations but disappointed investors with slower US procedure growth and a cautious full-year outlook. The company reported second quarter revenue of $2.89 billion, up 19% from a year earlier and above analysts' consensus estimate of $2.82 billion.
Intuitive Surgical shares fell more than 12% before the bell on Friday after it maintained its global growth forecast for procedures performed with its da Vinci surgical robots and warned that changes to some insurance plans could hurt demand.
Shares of Intuitive Surgical tumbled about 12% in premarket trading on Friday after the robotic surgery company issued a full-year procedure growth outlook that fell short of investor expectations, overshadowing stronger-than-expected second-quarter earnings and revenue. The maker of the da Vinci robotic surgery platform reported adjusted earnings of $2.80 per share for the quarter, comfortably ahead of analysts' estimates of $2.51.
Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Intuitive Surgical makes and supports the da Vinci surgical robot system. The company's flywheel is the sale of parts and services.
Intuitive Surgical, Inc. (ISRG) Q2 2026 Earnings Call Transcript
SUNNYVALE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2026.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ISRG and any ticker you trade — then tracks every position and per-strategy win rate.
